Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBI
Post# of 83
(Total Views: 1075)
Posted On: 01/18/2017 9:36:05 AM
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are trading lower by over 5% after the company announced disappointing phase II results for INGREZZA, a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor. Analysts are scrambling to find the proper price target and buy levels. Based on extensive stock chart analysis, the first major support level is at $32.75 The current stock price is $38.00. This will be a buy level for investors looking to pick up Neurocrine Biosciences on the cheap for a swing trade.
Stock market investors buy the Neurocrine Biosciences chart
Stock market investors buy the Neurocrine Biosciences chart
(0)
(0)Neurocrine Biosciences (NBIX) Stock Research Links
Scroll down for more posts ▼